Clareo Health | Observing the Real-world Non-interventional Study of Abiraterone Acetate Tablets (II) in Treating Chinese Patients With Metastatic Prostate Cancer
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
With
Jiangsu Hengrui Pharmaceutical Co., Ltd.
Northern Jiangsu People's Hospital
Age
18–any
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Queue One \& Queue Two: Age ≥ 18 years
Queue One \& Queue Two: Diagnosed with metastatic prostate cancer
Queue One: Researchers assess eligibility to use abiraterone acetate tablets (II) for treatment, or previous use, or ongoing treatment with abiraterone acetate tablets (II)
Queue One: Sign informed consent and voluntarily join this study
Queue 1: Male patients whose partners are women of childbearing potential should undergo surgical sterilization or agree to use effective contraception during the trial and for 3 weeks after the last administration of the study drug.
Queue Two: Previously used ordinary Abiraterone Acetate tablets continuously for more than 3 cycles
Queue 2: At least one efficacy assessment after medication
You may not be if
Queue One: Patients with severe liver dysfunction (Child-Pugh Class C)
Queue One: Currently participating in other clinical studies related to abiraterone acetate tablets (II)
Queue One \& Queue Two: Researchers determine other situations that are not suitable for inclusion in the study
Queue Two: Patients with severely missing medical record data
